New-onset diabetes and cardiovascular events in essential hypertensives: A 6-year follow-up study

Tsiachris, Dimitris; Tsioufis, Costas; Thomopoulos, Costas; Syrseloudis, Dimitris; Antonakis, Velissarios; Lioni, Louiza; Kallikazaros, Ioannis; Makris, Thomas; Papademetriou, Vasilios; Stefanadis, Christodoulos

doi:10.1016/j.ijcard.2010.08.041

Cited by 10 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 In a 6-year follow-up study, 140 out of 1,406 (10%) initially non-diabetic patients developed newonset diabetes and its close association with stroke. 21 These findings are a reminder that hypertensive patients are prone to develop diabetes, and the occurrence of diabetes substantially increases CV risk. In the KYOTO HEART Study, 144 out of 2,224 patients (6.5%) developed diabetes during the median follow-up period of 3.27 years, and the event risk in NewOnset Diabetes was higher than that in Final Non-Diabetes.…”

Section: Discussionmentioning

confidence: 96%

Retraction：Effects of Valsartan on Cardiovascular Morbidity and Mortality in High-Risk Hypertensive Patients With New-Onset Diabetes Mellitus

Kimura

Sawada

Shiraishi

et al. 2012

Circ J

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 96%

Retraction：Effects of Valsartan on Cardiovascular Morbidity and Mortality in High-Risk Hypertensive Patients With New-Onset Diabetes Mellitus

Kimura

Sawada

Shiraishi

et al. 2012

Circ J

View full text Add to dashboard Cite

“…Both studies exhibited increased CV risk in hypertensive subjects who developed new onset DM as compared with those who did not and the rates were similar to patients with pre-existing DM. Just recently, we reported that development of new onset DM in the setting of essential hypertension is associated with increased rates for cerebrovascular events, while no difference was observed in the incidence of CAD between hypertensives with new onset DM and those who did not develop DM during a follow-up period of 6 years [62].…”

Section: Cardiovascular Impact Of New Onset Dm During Antihypertensivmentioning

confidence: 86%

Choice of Antihypertensive Treatment in Subjects with Pre-Diabetes. Is There a Dream After the Navigator

Eleftheriadou

Tsioufis²,

Tsiachris³

et al. 2011

CVP

Self Cite

View full text Add to dashboard Cite

The majority of individuals with pre-diabetic states eventually appear to develop diabetes mellitus. During the pre-diabetic state, that may last many years, the risk of cardiovascular disease is modestly increased, with impaired glucose tolerance being slightly stronger predictor for future cardiovascular disease than impaired fasting glucose. The role of different antihypertensive drugs in the acceleration or the delay of diabetes onset is controversial. Agents that interrupt the renin-angiotensin system, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers are likely to be beneficial in the prevention of diabetes, while calcium channel blockers are thought to act metabolically neutral. In contrast, diuretics or β-blockers, and especially their combination, are thought to increase the incidence of diabetes. Carvedilol, a non-selective β-blocker with α(1)-blocking properties, and nebivolol, a third-generation highly selective β(1)- blocker with additional endothelial nitric oxide (NO)-mediated vasodilator activity have been shown to have a favorable effect on glucose metabolism compared with others β-blockers. Nevertheless, the key goal still remains to reduce blood pressure, which may require combination of different antihypertensive drug classes. Changes from diuretics and β- blockers to renin-angiotensin system inhibitors certainly have cost implications. However, treatment with angiotensin converting enzyme inhibitors and angiotensin receptor blockers may be cheaper in the long run, due to less risk of new-onset diabetes and other metabolic disturbances. Thus, for patients with pre-diabetes it is wise to choose medications with the least diabetogenic potential and until more data are available, it seems prudent to restrict use of diuretics and classic β- blockers.

show abstract

“…Diabetes mellitus is an important public health problem because of a high prevalence and increased morbidity and mortality. Cardiovascular involvement is frequent in diabetes and a major cause of death in diabetic patients [ 1 , 2 ]. Cardiac alterations are caused by both coronary atherosclerosis and diabetes-related cardiomyopathy.…”

Section: Introductionmentioning

confidence: 99%

Rutin administration attenuates myocardial dysfunction in diabetic rats

Guimarães

Muzio

Rosa

et al. 2015

Cardiovasc Diabetol

View full text Add to dashboard Cite

BackgroundOxidative stress plays a major role in diabetic cardiomyopathy pathogenesis. Anti-oxidant therapy has been investigated in preventing or treating several diabetic complications. However, anti-oxidant action on diabetic-induced cardiac remodeling is not completely clear. This study evaluated the effects of rutin, a flavonoid, on cardiac and myocardial function in diabetic rats.MethodsWistar rats were assigned into control (C, n = 14); control-rutin (C-R, n = 14); diabetes mellitus (DM, n = 16); and DM-rutin (DM-R, n = 16) groups. Seven days after inducing diabetes (streptozotocin, 60 mg/kg, i.p.), rutin was injected intraperitoneally once a week (50 mg/kg) for 7 weeks. Echocardiogram was performed and myocardial function assessed in left ventricular (LV) papillary muscles. Serum insulin concentration was measured by ELISA. Statistics: One-way ANOVA and Tukey’s post hoc test.ResultsGlycemia was higher in DM than DM-R and C and in DM-R than C-R. Insulin concentration was lower in diabetic groups than controls (C 2.45 ± 0.67; C-R 2.09 ± 0.52; DM 0.59 ± 0.18; DM-R 0.82 ± 0.21 ng/mL). Echocardiogram showed no differences between C-R and C. DM had increased LV systolic diameter compared to C, and increased left atrium diameter/body weight (BW) ratio and LV mass/BW ratio compared to C and DM-R. Septal wall thickness, LV diastolic diameter/BW ratio, and relative wall thickness were lower in DM-R than DM. Fractional shortening and posterior wall shortening velocity were lower in DM than C and DM-R. In papillary muscle preparation, DM and DM-R presented higher time to peak tension and time from peak tension to 50% relaxation than controls; time to peak tension was lower in DM-R than DM. Under 0.625 and 1.25 mM extracellular calcium concentrations, DM had higher developed tension than C.ConclusionRutin attenuates cardiac remodeling and left ventricular and myocardial dysfunction caused by streptozotocin-induced diabetes mellitus.

show abstract

New-onset diabetes and cardiovascular events in essential hypertensives: A 6-year follow-up study

Cited by 10 publications

References 28 publications

Retraction：Effects of Valsartan on Cardiovascular Morbidity and Mortality in High-Risk Hypertensive Patients With New-Onset Diabetes Mellitus

Retraction：Effects of Valsartan on Cardiovascular Morbidity and Mortality in High-Risk Hypertensive Patients With New-Onset Diabetes Mellitus

Choice of Antihypertensive Treatment in Subjects with Pre-Diabetes. Is There a Dream After the Navigator

Rutin administration attenuates myocardial dysfunction in diabetic rats

Contact Info

Product

Resources

About